Orizuru Therapeutics, Inc. (OZTx), a Japanese biotechnology company focusing on the research and development of iPSC-derived regenerative medicine, and PeptiGrowth Inc. (PeptiGrowth), a Japanese biotechnology company specializing in the development of synthetic peptide based growth factors, are pleased to announce the successful completion of the joint development project (first announced on August 23, 2023) for chemically synthesized peptide as an alternative to specific recombinant growth factors used in the manufacturing of regenerative medicine products developed by OZTx. The developed peptide was confirmed to bind to cellular receptors in a manner similar to the respective recombinant growth factor, inducing phosphorylation and signaling within the cells, thereby triggering differentiation and proliferation of iPSCs. [Read more…]
7 Important Trends Shaping the Future of Nursing Careers
As the healthcare landscape continues to evolve, nursing careers are experiencing profound changes. Innovative technology, shifting patient demographics, and new healthcare models are all contributing to the transformation of this once-stalwart profession. Nurses today are tasked with providing direct patient care and increasingly taking on roles in leadership, research, and advocacy. As we look into the future, several key trends are expected to define nursing careers, influencing everything from job opportunities to the necessary skill sets. [Read more…]
Eterna Therapeutics Releases Positive Preclinical Results for ERNA-101, an Allogenic iMSC Therapeutic
ERNA-101 is a cell therapy that utilizes iPSCs to create induced allogenic mesenchymal stem cells (iMSCs) that secrete interleukins IL-7 and IL-15.
Proof-of-concept study provides roadmap for treatment of ovarian cancer.
CAMBRIDGE, Mass., Jan. 14, 2025 — Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is designed to activate and regulate the immune system’s response to recognize and attack ovarian cancer cells. This successful proof-of-concept study demonstrated massive T cell infiltration after only one dose of ERNA-101, reduced tumor burden, and extended survival in mice with ovarian cancer. [Read more…]
IPS HEART’s Secures Orphan Drug Designation for iPSC-Derived Mesenchymal Progenitor Cell (MPC) Therapy, GIVI-MPC
In a groundbreaking development for the treatment of muscular dystrophies, IPS HEART received Orphan Drug Designation (ODD) from the U.S. FDA on January 13th, 2025, for its innovative stem cell therapy, GIVI-MPCs. GIVI-MPCs are mesenchymal progenitor cells derived from induced pluripotent stem cells (iPSCs) that have the potential to treat Becker Muscular Dystrophy (BMD). This milestone recognizes the therapy’s unprecedented ability to generate new skeletal muscle containing full-length dystrophin—a crucial protein missing or defective in individuals with BMD. [Read more…]
Uri Lee, CEO of Xcell Therapeutics, on Being a Pioneer in Serum-free, Chemically Defined Media
This is an interview with Uri Lee, CEO of Xcell Therapeutics. Xcell is an international leader in serum-free, chemically defined media. In this interview, we discuss the mission and purpose of Xcell Therapeutics, its product development pipeline, its rapid growth, and the company’s future goals. Enjoy. [Read more…]
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 336
- Next Page »